# An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

Source: https://onco.cc/trials/nct07806058/  
OnCo record `nct07806058` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of adebrelimab in pancreatic cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.

## Summary

An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors is a phase 1/2, randomised interventional study registered as NCT07806058 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 140 participants, started 2026-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: HRS-7172 + AG + SHR-1316; HRS-7172 + AG + SHR-1316;; HRS-7172 + AG;; HRS-7172 + AG + SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642+SHR-1316;; HRS-717 + HRS-4642;; HRS-717 + HRS-4642+SHR-1316;. Conditions listed: Pancreatic Cancer. Primary outcome: RDE in advanced pancreatic cancer with RAS mutation or amplification; Incidence and severity of adverse events (AEs) (per NCI-CTCAE V6.0 criteria); ORR assessed by the investigator. Pancreatic eligibility wording from the registry: "Locally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07806058
- Phase: 1/2
- Setting: An Open-Label, Multicenter, Phase IB/II Clinical Study of the Safety, Tolerability, and Efficacy of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT07806058: https://clinicaltrials.gov/study/NCT07806058

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07806058.json